Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1227049 | 0.78 | NAPRT (0.57) | CA2HCAR2HTTNAPRTCYP3A4 | |
| SCHEMBL17983732 | 0.77 | CAPN1 (0.46) | HCAR2RECQLCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16887645 | 0.76 | HCAR2 (0.41) | HCAR2NAPRTCYP1A2CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL1373539 | 0.76 | NAPRT (0.55) | CA2HCAR2HTTNAPRTCYP3A4 | |
| SCHEMBL2438139 | 0.76 | TBXAS1 (0.40) | HCAR2RECQLVNN1 | |
| SCHEMBL18071086 | 0.76 | HCAR2 (0.37) | HCAR2HTTNAPRTRECQLCYP1A2 | |
| SCHEMBL5178108 | 0.74 | AKT1 (0.43) | — | |
| SCHEMBL4536602 | 0.74 | CA2 (0.42) | CA2 | |
| Hydrochloric Acid SCHEMBL17610968 | 0.74 | HTR3E (0.38) | HCAR2 | |
| SCHEMBL794394 | 0.74 | NAPRT (0.69) | NAPRTRECQLCYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411395-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2012-02-01 | — | — | EP | claimed |
| EP-2411396-A2 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2012-02-01 | — | — | EP | claimed |
| EP-2411393-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2012-02-01 | — | — | EP | claimed |
| WO-2011132017-A1 | PYRIDO[3,4-D]PYRIMIDINYL ACETAMIDE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-10-27 | — | — | WO | claimed |
| WO-2010109334-A2 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-09-30 | — | — | WO | claimed |
| US-20250129091-A1 | THIENOPYRROLOTRIAZINE COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2025-04-24 | — | — | US | disclosed |
| US-20240336592-A1 | PHENYL- AND PYRIDOPYRAZOLE DERIVATIVES AS INHIBITORS OF DDR1 | REDX PHARMA PLC (GB) | 2024-10-10 | — | — | US | disclosed |
| WO-2024154979-A2 | NOVEL HETEROCYCLIC COMPOUNDS | 주식회사 이노보테라퓨틱스 | 2024-07-25 | — | — | WO | disclosed |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| US-11737463-B2 | Pyridine and pyrazine compounds | BASF SE (DE) | 2023-08-29 | — | — | US | disclosed |
| WO-2023134629-A1 | NUCLEAR TRANSPORT REGULATOR AND USE THEREOF | 上海海雁医药科技有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023134629-A1 | NUCLEAR TRANSPORT REGULATOR AND USE THEREOF | 上海海雁医药科技有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-8431556-B2 | C-21-keto lupane derivatives preparation and use thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2411393-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2012-02-01 | — | — | EP | disclosed |
| WO-2011132017-A1 | PYRIDO[3,4-D]PYRIMIDINYL ACETAMIDE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-10-27 | — | — | WO | disclosed |
| US-20110077228-A1 | NOVEL C-21-KETO LUPANE DERIVATIVES PREPARATION AND USE THEREOF | MOINET CHRISTOPHE | 2011-03-31 | — | — | US | disclosed |
| CN-1930134-B | Use of pyrimidine compounds for the preparation of parasiticides | NOVARTIS AG | 2010-06-16 | — | — | CN | disclosed |
| CN-1930134-A | Use of pyrimidine compounds for the preparation of parasiticides | NOVARTIS AG (CH) | 2007-03-14 | — | — | CN | disclosed |
| EP-0630244-A1 | MUSCARINIC AGONISTS | THE UNIVERSITY OF TOLEDO (US) | 1994-12-28 | — | — | EP | disclosed |
| WO-1993003726-A1 | MUSCARINIC AGONISTS | THE UNIVERSITY OF TOLEDO (US) | 1993-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11737463-B2 | Pyridine and pyrazine compounds | NDUFS5, IL5, NDUFS4 | CA2 1798/4885HCAR2 3288/4885HTT 2661/4885 |
| US-20250129091-A1 | THIENOPYRROLOTRIAZINE COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE | TPMT, TYMP, TBXA2R | CA2 3131/4885HCAR2 831/4885HTT 426/4885 |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NLRP3, NLRP1, NOD1 | CA2 3734/4885HCAR2 829/4885HTT 3966/4885 |
| US-20240336592-A1 | PHENYL- AND PYRIDOPYRAZOLE DERIVATIVES AS INHIBITORS OF DDR1 | DDR1, DDR2, DDRGK1 | CA2 4854/4885HCAR2 1997/4885HTT 3544/4885 |
| US-20110077228-A1 | NOVEL C-21-KETO LUPANE DERIVATIVES PREPARATION AND USE THEREOF | CYP51A1, CYP17A1, HSD17B7 | CA2 2643/4885HCAR2 1165/4885HTT 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.